Neurocrine BiosciencesFRA:NB3 +0.93%95 Net Margin % is 24.30% as of Mar. 2026, which is 166% above its 10-year median of 9.14. GuruFocus rates FRA:NB3 with a GF Score™ of 95/100 and a GF Value™ of €158.95 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 88.91% on this metric.
The historical rank and industry rank for Neurocrine Biosciences's Net Margin % or its related term are showing as below:
FRA:NB3'
s Net Margin % Range Over the Past 10 Years
Min: -940.6 Med: 9.14 Max: 38.94
Current: 21.55
FRA:NB3's Net Margin % is ranked better than 88.91% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:NB3: 21.55
Neurocrine Biosciences (FRA:NB3) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Neurocrine Biosciences Net Margin % Related Terms
Neurocrine Biosciences Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, ELAN, RGC: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a Net Margin % of 24.30% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Neurocrine Biosciences and its competitors. This is 166% above median its historical median of 9.14. According to the industry distribution chart, Neurocrine Biosciences ranks #106 out of 956 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Neurocrine Biosciences' Net Margin % too high?
Neurocrine Biosciences' current Net Margin % of 24.30% is 166% above median its 10-year median of 9.14. The Drug Manufacturers industry median Net Margin % is 5.56. Neurocrine Biosciences' value of 24.30% is 337.1% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #106 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Net Margin % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #106 out of 956 companies for Net Margin %. This places Neurocrine Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Neurocrine Biosciences' value of 24.30% is 337.1% above this benchmark. While the company's 10-year median is 9.14 vs. the industry median of 5.56, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Net Margin % of 24.30% is 337.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Net Margin % is 24.30%, which is 166% above median its own 10-year median of 9.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €158.95, compared to a current price of €141.20 — trading 11.2% below its estimated fair value. The current Net Margin % is 24.30%, which is 166% above median its 10-year median of 9.14 and 337.1% above the Drug Manufacturers industry median of 5.56. Neurocrine Biosciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Net Margin % is 24.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €141.20 is trading 11.2% below its estimated GF Value™ of €158.95.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for FRA:NB3:
Net Margin %: 24.30% (166% above median its 10-year median of 9.14)
GF Value™: €158.95 vs. price of €141.20 (11.2% below fair value)
Industry Position: 337.1% above the Drug Manufacturers median (#106 of 956)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score
Get the complete analysis for FRA:NB3
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
